TPST — Tempest Therapeutics Balance Sheet
0.000.00%
- $35.80m
- $15.32m
- 24
- 14
- 34
- 13
Annual balance sheet for Tempest Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 62.5 | 38.2 | 51.8 | 31.2 | 39.2 |
Net Total Receivables | 1.28 | 0.314 | — | — | — |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 71.1 | 40.9 | 69 | 33 | 40.4 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3.33 | 2.16 | 4.16 | 12.7 | 10.8 |
Other Long Term Assets | |||||
Total Assets | 75 | 43.4 | 73.2 | 46.1 | 51.6 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 12.5 | 7.99 | 20 | 7.28 | 9.41 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 16.4 | 10.4 | 37.1 | 28 | 24.8 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 58.5 | 33.1 | 36.1 | 18.1 | 26.8 |
Total Liabilities & Shareholders' Equity | 75 | 43.4 | 73.2 | 46.1 | 51.6 |
Total Common Shares Outstanding |